Gako-hitzak
peritoneo
multikistiko
anatomia
patologiko
Aipuak nola egin
Laburpena
Mesotelioma Peritoneal Multikistiko Onbera (MPMO) oso patologia ezohikoa da, batez ere ugalkortasun-aroko emakumeetan agertzen dena eta pronostiko ona duena. Mesotelioma gaiztoa ez bezala, ez da asbestoarekin erlazionatzen, baina haren etiopatogenia ez dago argi oraindik. Zenbait tratamendu mota probatu izan badira ere, gaur egun ez dago aukerako tratamendurik.
Donostia Unibertsitate Ospitalean (DUOn) MPMO duen 31 urteko emakume bat artatu zen duela gutxi. Diagnostikoa lesioaren biopsien azterketa anatomopatologikoaren bidez egin zen eta pazientea zitorredukzio-kirurgia eta kimioterapia intraperitoneal hipertermiko (HIPEC) bidez tratatu zen. Hiru hilera egindako OTan birgaixotze bat ikusi zen eta tratatzeko egindako ebakuntzako aurkikuntzengatik, asmo terapeutikoa alde batera utzi eta jarraipena egitea erabaki zen. Gaur egun pazienteak ez du sintomarik.
Lan honen xedea patologia ezohiko honi buruz gaur arte argitaratutako informazioa biltzea da, praktika klinikoan diagnostiko eta tratamendurako erabakian laguntzeko. Horretan laguntzeko DUOn izandako kasuaren berezitasunak azaldu dira.
Erreferentziak
Mutsaers SE. Mesothelial cells: Their structure, function and role in serosal repair. Respirology. 2002; 7: 171-191.
Sadler TW. Body cavities. Hemen: Sadler TW, editor. Langman’s Medical Embryology. 9. ed. Philadelphia: Lippincott Williams & Wilkins; 2004. 211-221.
Bridda A, Padoan I, Mencarelli R, Frego M. Peritoneal mesothelioma: a review. MedGenMed. 2007; 9(2):32.
Canty, Williams J, Volpe RJ, Yunan E. Benign cystic mesothelioma in a male. Am J Gas-troenterol. 1990; 85:311-315.
Mennemeyer R, Smith M. Multicystic, Peritoneal Mesothelioma. A Report with Elec-tron Microscopy of a Case Mimicking Intra-Abdominal Cystic Hygroma (Lymphangi-oma). Cancer. 1979; 44:692-698.
Rapisarda AMC, Cianci A, Caruso S, Vitale SG, Valenti G, Piombino E, Cianci S. Benign multicystic
mesothelioma and peritoneal inclusion cysts: are they the same clinical and histo-pathological
entities? A systematic review to find an evidence-based management. Arch Gynecol Obstet.
2018;297(6):1353-1375.
Søreide JA, Søreide K, Körner H, Søiland H, Greve OJ, Gudlaugsson E. Benign Perito-neal Cystic Mesothelioma. World J Surg. 2006; 30:560-566.
Weiss SW, Tavassoli FA. Multicystic mesothelioma. An analysis of pathologic findings and biologic behavior in 37 cases. Am J Surg Pathol. 1988; 12:737-746.
(9. Shakya VC, Agrawal CS, Karki S, Sah PL, Poudel P, Adhikary S. Benign cystic meso-thelioma of the peritoneum in a child—case report and review of the literature. J Pe-diatr Surg. 2011; 46:23–26.
Singh AP, Gupta AK, Ansari M, Barolia DK, Mathur V. Benign Cystic Mesothelioma in a Girl. APSP J Case Rep. 2017; 8:31.
Tuncer AA, Narcı A, Dilek FH, Baskın Embleton D, Çetinkurşun S. Benign cystic meso-thelioma in a child: case report and review of the literature. Balkan Med J 2016;33:232-234.
Khurram MS, Shaikh H, Khan U, Edens J, Ibrar W, Hamza A, Zaka A, Bano R, Hadid T. Benign
Multicystic Peritoneal Mesothelioma: A Rare Condition in an Uncommon Gender. Case Rep Pathol.
2017;2017:9752908.
Ross MJ, Welch WR, Scully RE. Multilocular peritoneal inclusion cysts (so-called cystic mesotheliomas). Cancer. 1989; 64:1336-1346.
Groisman GM, Kerner H. Multicystic mesothelioma with endometriosis. Acta Obstet Gynecol Scand. 1992; 71:642-644.
Kurisu Y, Tsuji M, Shibayama Y, Yamada T, Ohmichi M. Multicystic mesothelioma caused by endometriosis: 2 case reports and review of the literature. Int J Gynecol Pathol. 2011; 30:163-166.
D’Antonio A, Baldi1 C, Addesso M, Napolitano C. The first case of benign multicystic mesothelioma presenting as a splenic mass. Ecancermedicalscience. 2016;10:678.
González-Moreno S, Yan H, Alcorn KW, Sugarbaker PH. Malignant transformation of "benign" cystic mesothelioma of the peritoneum. J Surg Oncol. 2002;79(4):243-251.
Luna-Abanto J, Mendoza-Tisoc G, Huanca-Amesquita L, Berrospi-Espinoza F. Benign Multicystic Peritoneal Mesothelioma in a Male Teen: Case Report and Review of the Literature. P R Health Sci J. 2020;39(2):222-225.
Bernstein EM, Tate A, Silasi DA, Rutherford T. Benign multicystic mesothelioma: a case report of three sisters. Rare Tumors. 2009; 1:46.
Chand MT, Edens J, Lin T, Anderson I, Berri R. Benign multicystic peritoneal mesothe-lioma - literature review and update. Autops Case Rep [Internet]. 2020;10(3):e2020159.
Park JY, Kim KW, Kwon HJ, Park MS, Kwon GY, Jun SY, Yu ES. Peritoneal mesotheliomas: clinicopathologic features, CT findings, and differential diagnosis. AJR Am J Roent-genol. 2008;191(3):814-825.
Hassan A., Sinclair D. Case report: Calcification in benign cystic peritoneal mesotheli-oma. Clin Radiol. 1993;48: 66-67.
Stoupis C, Ros PR, Abbitt PL, Burton SS, Gauger J. Bubbles in the belly: imaging of cystic mesenteric or omental masses. Radiographics. 1994;14(4):729-737.
Baeyens P, Pringot J, Raat A, Van Belle K, Van Campenhoudt M. Benign cystic perito-neal mesothelioma. JBR-BTR. 2004;87(3):114-115.
Noiret B, Renaud F, Piessen G, Eveno C. Multicystic peritoneal mesothelioma: a sys-tematic review of the literature. Pleura Peritoneum. 2019;4(3):20190024.
Dzieniecka M, Kałużyński A. Benign multicystic peritoneal mesothelioma (BMPM. - case report and review of the literature. Pol J Pathol. 2011;62(2):122-124.
Snyder JA, Carman R Jr, Aggon AA, Cardinale JP. Benign multicystic peritoneal meso-thelioma: A rare case presenting as pneumoperitoneum and pneumotosis intestinalis. J Gastrointest Oncol. 2011;2(1):55-58.
Ellenson LH, Pirog EC. The Female Genital Tract. Hemen: Kumar V, Abbas AK, Aster JC, editors. Robbins and Cotran Pathologic Basis of Disease. 9.ed. Philadelphia: Saun-ders/Elsevier; 2015.1010-1012.
Momeni M, Pereira E, Grigoryan G, Zakashansky K. Multicystic benign cystic meso-thelioma presenting as a pelvic mass. Case Rep Obstet Gynecol. 2014;2014:852583.
Cheung AN, Kim K-R, Longacre TA, Malpica A. Tumours of the peritoneum. Hemen: Who Classification of Tumours Editorial Board, editor. Female genital tumours : WHO Classification of Tumours, 5th Edition. Lyon: International Agency for Research on Cancer; 2020. 181-183.
Bhandarkar DS, Smith VJ, Evans DA, Taylor TV. Benign cystic peritoneal mesothelio-ma. J Clin Pathol. 1993;46:867-868.
Safioleas MC, Constantinos K, Michael S, Konstantinos G, Constantinos S, Alkiviadis K. Benign multicystic peritoneal mesothelioma: A case report and review of the litera-ture. World J Gastroenterol 2006; 12(35): 5739-5742.
Husain AN, Colby TV, Ordóñez NG, Allen TC, Attanoos RL, Beasley MB, Butnor KJ, Chi-rieac LR, Churg AM, Dacic S, Galateau-Sallé F, Gibbs A, Gown AM, Krausz T, Litzky LA, Marchevsky A, Nicholson AG, Roggli VL, Sharma AK, Travis WD, Walts AE, Wick MR. Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group. Arch Pathol Lab Med. 2018;142(1):89-108.
Iversen OH, Hovig T, Brandtzaeg P. Peritoneal, benign, cystic mesothelioma with free-floating cysts, re-examined by new methods. A case report. APMIS. 1988;96(2):123-127.
Ordóñez NG. The diagnostic utility of immunohistochemistry and electron microscopy in distinguishing between peritoneal mesotheliomas and serous carcinomas: a com-parative study. Mod Pathol. 2006;(1):34-48.
Shin HD, Kim SB. Benign Cystic Mesothelioma Misdiagnosed as Peritoneal Carcino-matosis. Case Rep Gastroenterol. 2016;10(1):115-120.
Guo Y, Chirieac LR, Bueno R, Pass H, Wu W, Malinowska IA, Kwiatkowski DJ. Tsc1-Tp53 loss induces mesothelioma in mice, and evidence for this mechanism in human mes-othelioma. Oncogene, 2014; 33: 3151-3160.
Carella R, Deleonardi G, D’Errico A, Salerno A, Egarter-Vigl E, Seebacher C, Donazzan G, Grigioni WF. Immunohistochemical panels for differentiating epithelial malignant mesothelioma from lung adenocarcinoma: a study with logistic regression analysis. Am J Surg Pathol. 2001;25(1):43-50.
Jo VY, Cibas ES, Pinkus GS. Claudin-4 immunohistochemistry is highly effective in dis-tinguishing adenocarcinoma from malignant mesothelioma in effusion cytology. Can-cer Cytopathol. 2014;122(4):299-306.
Churg A, Sheffield BS, Galateau-Salle F. New Markers for Separating Benign From Malignant Mesothelial Proliferations: Are We There Yet?. Arch Pathol Lab Med. 2016; 140 (4): 318–321.
Murali R, Wiesner T, Scolyer RA. Tumours associated with BAP1 mutations. Pathology. 2013;45:116–126.
Hwang HC, Sheffield BS, Rodriguez S, Thompson K, Tse CH, Gown AM, Churg A. Utility of BAP1 immunohistochemistry and p16 (CDKN2A. FISH in the diagnosis of malignant mesothelioma in effusion cytology specimens. Am J Surg Pathol. 2016;40(1):120-126.
Sheffield BS, Hwang HC, Lee AF, Thompson K, Rodriguez S, Tse CH, Gown AM, Churg A. BAP1 Immunohistochemistry and p16 FISH to separate benign from malignant mesothelial proliferations. Am J Surg Pathol. 2015;39:977–982.
Romagosa, C., Simonetti, S., López-Vicente, L. Mazo A, Lleonart ME, Castellvi J, Ra-mon y Cajal S. p16Ink4a overexpression in cancer: a tumor suppressor gene associat-ed with senescence and high-grade tumors. Oncogene. 2011; 30: 2087–2097.
Chung CT, Santos Gda C, Hwang DM, Ludkovski O, PintilieM, Squire JA, Tsao MS. FISH assay development for the detection of p16/CDKN2A deletion in malignant pleural mesothelioma. J Clin Pathol. 2010; 63:630-634.
Tangjitgamol S, Erlichman J, Northrup H, Malpica A, Wang X, Lee EE, Kavanagh JJ. Benign multicystic peritoneal mesothelioma: cases reports in the family with diver-ticulosis and literature review. Int J Gynecol Cancer 2005;15:1101-1107.
Pathology Outlines [internet] Michigan: Pathology Outlines; 2021 Multicystic Meso-thelioma; [kontsulta, 2021/04/13]. Multicystic Mesothelioma; [8 pantaila ggb]. Erabilgarri: https://www.pathologyoutlines.com/topic/pleuraperitmulticysticmeso.html.
Aprea G, Guida F, Canfora A, Ferronetti A, Giugliano A, Ciciriello MB, Savanelli A, Amato B. Mesenteric cystic lymphangioma in adult: a case series and review of the literature. BMC Surg. 2013 16;13(Suppl 1):A4.
Abdulraheem AK, Al Sharie AH, Al Shalakhti MH, Alayoub SY, Al-Domaidat HM, El-Qawasmeh AE. Mesenteric cystic lymphangioma: A case report. Int J Surg Case Rep. 2021;80:105659.
Jerraya H, Ghariani W, Blel A, Gaja A, Dziri C. Benign multicystic peritoneal mesothe-lioma presenting as a ghost abdominal mass. Diagn Interv Imaging. 2016;97(3):361-163.
Scherpereel A, Astoul P, Baas P, Berghmans T, Clayson H, de Vuyst P, Dienemann H, Galateau-Salle F, Hennequin C, Hillerdal G, Le Péchoux C, Mutti L, Pairon JC, Stahel R, van Houtte P, van Meerbeeck J, Waller D, Weder W;Guidelines of the European Res-piratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. Eur Respir J. 2010 Mar;35(3):479-95.
Zahid A, Clarke L, Carr N, Chandrakumaran K, Tzivanakis A, Dayal S, Mohamed F, Cec-il T, Moran BJ. Outcomes of multicystic peritoneal mesothelioma treatment with cy-toreductive surgery and hyperthermic intraperitoneal chemotherapy. BJS Open. 2021;5(2): zraa001.
Nizri E, Baratti D, Guaglio M, Sinukumar S, Cabras A, Kusamura S, Deraco M. Mul-ticystic mesothelioma: operative and long-term outcomes with cytoreductive surgery and hyperthermic intra peritoneal chemotherapy. Eur J Surg Oncol. 2018; 44(7):1100-1104.
Baratti D, Kusamura S, Nonaka D, Oliva GD, Laterza B, Deraco M. Multicystic and well-differentiated papillary peritoneal mesothelioma treated by surgical cytoreduc-tion and hyperthermic intra-peritoneal chemotherapy (HIPEC). Ann Surg Oncol. 2007;14(10):2790-2797.
Rosen DM, Sutton CJ. Use of the potassium titanyl phosphate (KTP. laser in the treat-ment of benign multicystic peritoneal mesothelioma. Br J Obstet Gynaecol. 1999;106:505-506.
Letterie GS, Yon JL. The antiestrogen tamoxifen in the treatment of recurrent benign cystic mesothelioma. Gynecol Oncol. 1998;70:131-133.
Letterie GS, Yon JL. Use of a long-acting GnRH agonist for benign cystic mesothelio-ma. Obstet Gynecol. 1995;85:901-903.
Nozawa S, Iwata T, Yamashita H, Banno K, Kubushiro K, Aoki R et al. Gonadotropin-releasing hormone analogue therapy for peritoneal inclusion cysts after gynecologi-cal surgery. J Obstet Gynaecol Res. 2000;26:389-393.
Jeong JY, Kim SH. Sclerotherapy of peritoneal inclusion cysts: preliminary results in seven patients. Korean J Radiol. 2001;2:164-170.
Lim HK, Cho JY, Kim SH. Sclerotherapy of peritoneal inclusion cysts: a long-term eval-uation study. Abdom Imaging. 2010;35:431-436.
Abraham RT, Gibbons JJ. The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy. Clin Cancer Res. 2007;13(11):3109-3114. Pubmed.
Stallone G, Schena A, Infante B et al. Sirolimus for Kaposi’s sarcoma in renal trans-plant recipients. N Engl J Med. 2005;352:1317–1323.
Stallone G, Infante B, Cormio L, Macarini L, Grandaliano G. Rapamycin treatment for benign multicystic peritoneal mesothelioma: a rare disease with a difficult manage-ment. Am J Case Rep. 2017;18:632-636.
Sehgal SN. Sirolimus: its discovery, biological properties, and mechanism of action. Transplant Proc. 2003;35(3):7-14.
DeStephano DB, Wesley JR, Heidelberger KP, Hutchinson RJ, Blane CE, Coran AG. Primitive cystic hepatic neoplasm of infancy with mesothelial differentiation: report of a case. Pediatr Pathol 1985;4:291-302.
Hammar SP, Dacic S. Immunohistology of Lung and Pleural Neoplasm. In: Dabbs DJ, editor. Diagnostic Immunohistochemistry. 5th edition. Philadelphia: Saun-ders/Elsevier; 2017. 415-463.
Hicks D, Dell'Orto P, Falzon M, Hoff KD, Levy YY, McMahon L, Miller K, Russo L, Viale G. Immunohistochemical Performance of Estrogen and Progesterone Receptor Anti-bodies on the Dako Omnis Staining Platform: Evaluation in Multicenter Studies. Appl Immunohistochem Mol Morphol. 2017;25(5):313-319.
Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Phys-iol. 2000 Mar;182(3):311-322.
Enríquez-Navascués JM, Beguiristain A, Arteaga X, La Casta A, Egaña L, Iraeta H, Ro-teta L, Gaztañaga I, Aranguren A, Adell AB, Zabarte M, Alberdi, G. Lizeaga G, Ripa C, Fernández I, Galparsoro, Orube. Programa de Carcinomatosis Peritoneal. 2018. Osakidetza, Donostialdeko ESI, Donostia Unibertsitate Ospitalea. 2018 [argitaratu ga-bea].
Mohamed F, Sugarbaker PH. Peritoneal mesothelioma. Curr Treat Options Oncol. 2002;3(5):375-86.
Alexander HR Jr, Bartlett DL, Pingpank JF, DL, Pingpank JF, Libutti SK, Royal R, Hughes MS, Holtzman M, Hanna N, Turner K, Beresneva T, Zhu Y. Treatment factors associat-ed with long-term survival after cytoreductive surgery and regional chemotherapy for patients with malignant peritoneal mesothelioma. Surgery. 2013;153(6):779-786.
España. Real Decreto 1299/2006, de 10 de noviembre, por el que se aprueba el cua-dro de enfermedades profesionales en el sistema de la Seguridad Social y se estable-cen criterios para su notificación y registro. [Internet]. Boletín Oficial del Estado. 2006 [Kontsulta: 2023-06-23]. 34 or.
Eskuragarri: https://www.boe.es/buscar/pdf/2006/BOE-A-2006-22169-consolidado.pdf.
Li LT, Jiang G, Chen Q, Zheng JN. Ki67 is a promising molecular target in the diagnosis of cancer (review). Mol Med Rep. 2015;11(3):1566-1572.
Padmanabhan N, Ishibashi H, Nishihara K, Sako S, Katayama K, Wakama S, Kamada Y, Yonemura Y. Multicystic peritoneal mesothelioma treated with complete cytoreduc-tive surgery, peritonectomy and hyperthermic intra-peritoneal chemotherapy-A case report. Int J Surg Case Rep. 2020;74:152-157.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright (c) 2024 Osagaiz: osasun-zientzien aldizkaria